Clinical trial
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
NCT05768178 is registered in ClinicalTrials.gov with Cancer Research UK as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
- Lead sponsor
- Cancer Research UK
- Phase
- Phase 2/3
- Overall status
- Recruiting
- Start date
- March 1, 2023
- Completion date
- October 31, 2029
- Enrollment
- 30 (estimated)
- Sites
- 16
Conditions
As the registry lists them; a condition with its own page is linked.
carcinoma, non-small-cell lung, colorectal neoplasms, erdheim-chester disease, glioma, haematological malignancy, laryngeal neoplasms, melanoma, multiple myeloma, ovarian neoplasms, solid tumour, thyroid cancer, papillary, thyroid carcinoma, anaplastic